StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Lenvima (lenvatinib by Quarter

Lenvima (lenvatinib — Eisai oncology alliance revenue) — International sales ($M) ($M)

QuarterlyAnnual

Merck Lenvima (lenvatinib: $90M in Q2 2026, up 8.4% from a year earlier.

Latest, Q2 2026
90
Period ended Jun 30, 2026
Change on a year earlier
+8.4%
83 in Q2 2025
History
37 quarters
Since Q2 2017
Sources
29
Documents cited below

Where the Q2 2026 figure comes from

“|| Alliance Revenue – Lenvima (2) | 283 | 265 | 7 | 194 | 183 | 6 | 90 | 83 | 8”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLenvima (lenvatinib — Eisai oncology alliance revenue) — International sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202690+8.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202680+11.1%Form 10-Q (filed 2026-05-04) ↗
Q4 2025Dec 31, 202580+9.6%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202581+3.8%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202583+13.7%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202572-12.2%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 202473+62.2%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202478-22.0%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 202473-7.6%Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2024Mar 31, 202482+3.8%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 202345-27.4%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 2023100+66.7%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 202379-23.3%Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2023Mar 31, 202379+11.3%Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 202262-17.3%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 202260-18.9%Form 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗

Breakdown

What makes up lenvima (lenvatinib

Cite this data

StockData. (2026). Merck Lenvima (lenvatinib ($M), quarterly Q2 2017–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-lenvima-intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.